High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory H odgkin lymphoma ( HL )
Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
PB1903 IMPROVEMENT IN PATIENT‐REPORTED OUTCOMES (PROS) AND FATIGUE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB (IBR) MONOTHERAPY: REPORT OF REAL WORLD EXPERIENCE
Mela Osorio, M.J., Pavlovsky, A., Fernández, I., Pavlovsky, C., Sackmann Massa, F., Ferrari, L., Riddick, M., Pavlovsky, M.A.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL)
Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
Unit for thinning out and plant cultivation
Borysyuk, V.O, Zakharenko, A.O, Zyev, M.M, Pavlovsky, M.A, Pavlyuk, V.M, Pilkevych, S.M, Pryshchepa, S.M
Year of Publication 01.07.1999
Get more information
Year of Publication 01.07.1999
Book